- Home
- GBLI vs ALMS Comparison
GBLI vs ALMS Comparison
Compare GBLI & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- ALMS
- Stock Information
- Founded
- GBLI 2016
- ALMS 2021
- Country
- GBLI United States
- ALMS United States
- Employees
- GBLI N/A
- ALMS N/A
- Industry
- GBLI Property-Casualty Insurers
- ALMS
- Sector
- GBLI Finance
- ALMS
- Exchange
- GBLI Nasdaq
- ALMS NYSE
- Market Cap
- GBLI 476.1M
- ALMS 402.6M
- IPO Year
- GBLI 2003
- ALMS 2024
- Fundamental
- Price
- GBLI $30.01
- ALMS $5.61
- Analyst Decision
- GBLI
- ALMS Strong Buy
- Analyst Count
- GBLI 0
- ALMS 7
- Target Price
- GBLI N/A
- ALMS $26.83
- AVG Volume (30 Days)
- GBLI 6.4K
- ALMS 474.1K
- Earning Date
- GBLI 05-07-2025
- ALMS 05-14-2025
- Dividend Yield
- GBLI 4.57%
- ALMS N/A
- EPS Growth
- GBLI N/A
- ALMS N/A
- EPS
- GBLI 1.99
- ALMS N/A
- Revenue
- GBLI $437,447,000.00
- ALMS $17,389,000.00
- Revenue This Year
- GBLI $8.70
- ALMS N/A
- Revenue Next Year
- GBLI $14.56
- ALMS N/A
- P/E Ratio
- GBLI $15.39
- ALMS N/A
- Revenue Growth
- GBLI N/A
- ALMS N/A
- 52 Week Low
- GBLI $26.94
- ALMS $3.18
- 52 Week High
- GBLI $37.00
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- GBLI 51.81
- ALMS N/A
- Support Level
- GBLI $28.82
- ALMS N/A
- Resistance Level
- GBLI $30.98
- ALMS N/A
- Average True Range (ATR)
- GBLI 1.11
- ALMS 0.00
- MACD
- GBLI 0.40
- ALMS 0.00
- Stochastic Oscillator
- GBLI 74.15
- ALMS 0.00
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.